CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 261 enrolled
Drug / intervention
BMS-986165drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03920267
NCT03920267Phase 2Completed
CompareCT.gov

A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus

Bristol-Myers Squibb·interventional·Posted Apr 18, 2019·Updated Mar 20, 2026

In Brief

A Phase 2 clinical trial evaluating BMS-986165 for Systemic Lupus Erythematosus. Completed, enrolled 261 participants across 98 sites in 14 countries.

Detailed Summary

The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSystemic Lupus Erythematosus
CountriesArgentina, Brazil, Canada, Colombia, Hungary, Japan, Mexico, Poland, Romania, Russia, South Korea, Spain, Taiwan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 18, 2019
Enrollment StartMar 26, 2019
Primary CompletionMar 21, 2025
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 7.2 years ago

Interventions

BMS-986165drug

Specified dose on specified days